Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Ketoconazole

Related Products

Hot Products

Name

Ketoconazole

EINECS 265-667-4
CAS No. 65277-42-1 Density 1.38 cm3
PSA 69.06000 LogP 4.20870
Solubility Soluble in DMSO, ethanol, chloroform, water, and methanol. Melting Point 146 °C
Formula C26H28Cl2H4O4 Boiling Point 753.4 °C at 760 mmHg
Molecular Weight 531.439 Flash Point 409.4 °C
Transport Information UN 2811 6.1/PG 3 Appearance White powder
Safety 36-45-36/37/39-26 Risk Codes 25-36/37/38-23/24/25
Molecular Structure Molecular Structure of 65277-42-1 (Ketoconazole) Hazard Symbols ToxicT
Synonyms

Ketoconazole [USAN:BAN:INN:JAN];Ketoconazol [INN-Spanish];1-acetyl-4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine;Ketoconazole (JAN/USP);Nizoral (TN);KW-1414;(+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine;Nizoral;cis-1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1h-imidazol-1-ylmethyl)-1,3-diox olan- 4-yl)methoxy)phenyl)-piperazine;Prestwick_744;Fungarest;1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone;Fungoral;Ketoconazol;Piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis-;Ketoderm;cis-1-Acetyl-4-[4-[2-(2,4-dichlorophenyl)-2-(1H-cmidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]pipenazine;

Article Data 12

Ketoconazole Synthetic route

46503-52-0

1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanone

(+/-)-1-acetyl-4-<4-(2,3-dihydroxypropoxy)phenyl>piperazine

65277-42-1

ketoconazole

Conditions
ConditionsYield
With trifluoroacetic acid In dimethyl sulfoxide; toluene for 16h; Reagent/catalyst; Temperature; Reflux;80%
288-32-4

1H-imidazole

142128-67-4

(2R,4S)-cis-2-(bromomethyl)-2-(2,4-dichlorophenyl)-4-<<4-(4-acetylpiperazin-1-yl)phenoxy>methyl>-1,3-dioxolane

A

65277-42-1

ketoconazole

B

142004-25-9

(2R,4S)-cis-2-(hydroxymethyl)-2-(2,4-dichlorophenyl)-4-<<4-(4-acetylpiperazin-1-yl)phenoxy>methyl>-1,3-dioxolane

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl acetamide for 4h; Heating;A 53%
B 10%
170210-43-2

(2R,4R)-(+)-<2-(2,4-dichlorophenyl)-2-<(1H-imidazol-1-yl)methyl>-1,3-dioxolan-4-yl>methyl methanesulfonate

67914-60-7, 89929-31-7

N-acetyl-N'-(4-hydroxyphenyl)piperazine

65277-42-1

ketoconazole

Conditions
ConditionsYield
With sodium hydride 1.) DMSO, RT, 1 h, 2.) DMSO, 80 deg C, 4 h; Yield given. Multistep reaction;

[cis-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl] 4-methyl-benzenesulfonate

67914-60-7, 89929-31-7

N-acetyl-N'-(4-hydroxyphenyl)piperazine

65277-42-1

ketoconazole

Conditions
ConditionsYield
With sodium hydride In dimethyl sulfoxide at 0 - 80℃;
56621-48-8

1-(4-hydroxyphenyl)piperazine

65277-42-1

ketoconazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: pyridine / CH2Cl2
2: K2CO3 / methanol / 20 °C
3: NaH / dimethylsulfoxide / 0 - 80 °C
View Scheme
133345-21-8

1-(4-Acetoxyphenyl)-4-acetylpiperazine

65277-42-1

ketoconazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: K2CO3 / methanol / 20 °C
2: NaH / dimethylsulfoxide / 0 - 80 °C
View Scheme
70894-66-5, 134071-29-7, 138866-89-4

(2R,4R)-(+)-<2-(2,4-dichlorophenyl)-2-<(1H-imidazol-1-yl)methyl>-1,3-dioxolan-4-yl>methyl benzoate

65277-42-1

ketoconazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: NaOH / dioxane / Heating
2: pyridine
3: NaH / dimethylsulfoxide / 0 - 80 °C
View Scheme
170210-42-1

(2R,4S)-(+)-2-(2,4-dichlorophenyl)-2-<(1H-imidazol-1-yl)methyl>-1,3-dioxolane-4-methanol

65277-42-1

ketoconazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: pyridine
2: NaH / dimethylsulfoxide / 0 - 80 °C
View Scheme
Multi-step reaction with 2 steps
1: 81 percent / pyridine / 16 h / 0 °C
2: 1.) NaH / 1.) DMSO, RT, 1 h, 2.) DMSO, 80 deg C, 4 h
View Scheme

(2R,4R)-(+)-<2-(2,4-dichlorophenyl)-2-<(1H-imidazol-1-yl)methyl>-1,3-dioxolan-4-yl>methyl benzoate nitrate

65277-42-1

ketoconazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 89 percent / 50percent aq. NaOH / dioxane / 0.5 h / Heating
2: 81 percent / pyridine / 16 h / 0 °C
3: 1.) NaH / 1.) DMSO, RT, 1 h, 2.) DMSO, 80 deg C, 4 h
View Scheme
79156-75-5

1-(4-{4-[2-(2,4-dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone

A

65277-42-1

ketoconazole

B

142128-58-3

(2R,4R)-Ketoconazole

D

142128-60-7

(2S,4S)-Ketoconazole

Conditions
ConditionsYield
With methanol; sodium dodecyl-sulfate; 2,3,6-trimethyl-beta-cyclodextrin; sodium hydroxide In aq. phosphate buffer at 25℃; pH=2.5; pH-value; Reagent/catalyst; Temperature; Resolution of racemate;

Ketoconazole Chemical Properties

Structure of Ketoconazole (CAS NO.65277-42-1):
 
Molecular Formula:C26H28Cl2N4O4
Molecular Weight:531.44
EINECS:265-667-4 
Index of Refraction: 1.642
Molar Refractivity: 139.11 cm3
Molar Volume: 384.9 cm3
Polarizability: 55.15×10-24cm3
Surface Tension: 52.1 dyne/cm
Density: 1.38 g/cm3
Flash Point: 409.4 °C
Enthalpy of Vaporization: 109.78 kJ/mol
Melting point: 146 oC
Boiling Point: 753.4 °C at 760 mmHg
Vapour Pressure: 1.39E-22 mmHg at 25 °C
Physical Appearance: White Powder
Product Categories: Active Pharmaceutical Ingredients;Organics;Antifungals for Research and Experimental Use;Antitumors for Research and Experimental Use;Biochemistry;Antibiotic Explorer;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API;API's;Antifungal

Ketoconazole History

 Ketoconazole was discovered in 1976 and released in 1981. It followed griseofulvin as one of the first available oral treatments for fungal infections.
 

Ketoconazole Uses

Usage of Ketoconazole (CAS NO.65277-42-1):
1.Inhibits cytochrome P-450 dependent steps in the biosynthesis of steroid hormones in vivo.
2.Antimetastatic and antineoplastic activity.
3.Orally active 5-lipoxygenase and thromboxane synthase inhibitor.

Ketoconazole Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo oral 450mg/kg/90D- (450mg/kg) ENDOCRINE: EVIDENCE OF THYROID HYPOFUNCTION British Medical Journal. Vol. 293, Pg. 993, 1986.
dog LD50 intravenous 23300ug/kg (23.3mg/kg)   Medicamentos de Actualidad. Vol. 17, Pg. 373, 1981.
dog LD50 oral 178mg/kg (178mg/kg)   Medicamentos de Actualidad. Vol. 17, Pg. 373, 1981.
guinea pig LD50 intravenous 23300ug/kg (23.3mg/kg)   Medicamentos de Actualidad. Vol. 17, Pg. 373, 1981.
guinea pig LD50 oral 178mg/kg (178mg/kg)   Medicamentos de Actualidad. Vol. 17, Pg. 373, 1981.
man LDLo oral 45mg/kg/17D-I (45mg/kg) BEHAVIORAL: COMA

LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED"
Gut. Vol. 26, Pg. 636, 1986.
man TDLo oral 49mg/kg/17D-I (49mg/kg) LIVER: OTHER CHANGES Gastroenterology. Vol. 86, Pg. 503, 1984.
mouse LD50 intraperitoneal 2937mg/kg (2937mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 18, Pg. 474, 1987.
mouse LD50 intravenous 32mg/kg (32mg/kg)   Antimicrobial Agents and Chemotherapy. Vol. 33, Pg. 895, 1989.
mouse LD50 oral 618mg/kg (618mg/kg)   Medicamentos de Actualidad. Vol. 17, Pg. 373, 1981.
mouse LD50 subcutaneous > 4gm/kg (4000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 18, Pg. 474, 1987.
rat LD50 intraperitoneal 1474mg/kg (1474mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 18, Pg. 474, 1987.
rat LD50 intravenous 86mg/kg (86mg/kg)   Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 23, Pg. 1, 1982.
rat LD50 oral 166mg/kg (166mg/kg)   Medicamentos de Actualidad. Vol. 17, Pg. 373, 1981.
rat LD50 subcutaneous > 2400mg/kg (2400mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 18, Pg. 474, 1987.
women LDLo oral 264mg/kg/66D- (264mg/kg) LIVER: OTHER CHANGES Gastroenterology. Vol. 86, Pg. 503, 1984.
women LDLo oral 412mg/kg/15W- (412mg/kg) BEHAVIORAL: COMA

LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE"

LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED"
Gut. Vol. 26, Pg. 636, 1986.
women TDLo oral 60mg/kg (60mg/kg) LIVER: OTHER CHANGES Gastroenterology. Vol. 86, Pg. 503, 1984.
 

Ketoconazole Safety Profile

Hazard Codes: ToxicT
Risk Statements: 25-36/37/38-23/24/25 
R25 :Toxic if swallowed. 
R36/37/38:Irritating to eyes, respiratory system and skin. 
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed.
Safety Statements: 36-45-36/37/39-26 
S36:Wear suitable protective clothing. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: TK7912300
HazardClass: 6.1(b)
PackingGroup: III
Poison by ingestion and intravenous routes. Experimental reproductive effects. Human systemic effects: liver changes, evidence of thyroid hypofunction. Human mutation data reported. Note: May be associated with hepatic toxicity. When heated to decomposition it emits toxic fumes of Cl and NOx.

Ketoconazole Specification

  Ketoconazole (CAS NO.65277-42-1), its Synonyms are (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine ; Ketoconazolum ; Ketoderm ; Ketoisdin ; Ketozole ; Kuric ; Onofin K ; Orifungal M ; Panfungol .

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 65277-42-1